Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumryz in Spasmodic Dysphonia and Voice Tremor
NCT07041203Phase 1Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium oxybate in Spasmodic dysphonia (SD) and essential voice tremor (EVT). Primary endpoint: Efficacy of Lumryz at 4 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sodium oxybate
03
Conditions
Spasmodic dysphonia (SD)essential voice tremor (EVT)
Beyond the preview
Go deeper on NCT07041203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07041203.